A WSJ NEWS ROUNDUP
March 5, 2008; Page B10
Barr Pharmaceuticals Inc. said it may adjust its earnings forecast in the wake of a patent victory that paves the way for it to make a generic version of a popular contraceptive pill.
Monday, a U.S. District Court in New Jersey ruled in favor of Barr, invalidating a patent protecting Germany-based Bayer AG's Yasmin birth-control pill. Barr, based in Woodcliff Lake, N.J., filed with the U.S. Food and Drug Administration to make a generic version of Yasmin in 2005, and Bayer sued, claiming patent infringement.
Barr Chairman and Chief Executive Bruce Downey said, "Clearly, this is a positive development for the company, and we are evaluating what the potential impact could be on our earnings guidance for 2008."
Yasmin generated sales of $488.2 million in the U.S. last year.
Bayer, meanwhile, said it "will consider legal options," adding, "The company will vigorously defend its intellectual property."
Bayer shares took a hit in Frankfurt, falling 5.8% to ?7.29 ($71.93). In 4 p.m. New York Stock Exchange trading, Barr shares were 8.3% higher at $49.47.
Bayer acquired Yasmin when it bought Schering AG in 2006. Last year, the oral contraceptives of the Yasmin, Yaz and Yasminelle family generated sales of $1.58 billion, making it Bayer's best-selling pharmaceutical product for the year. [标签:content1][标签:content2]
作者:admin@医学,生命科学 2011-02-18 05:14